PDF Cover

Nedosiran Sodium Market

The market for Nedosiran Sodium was estimated at $408 million in 2024; it is anticipated to increase to $595 million by 2030, with projections indicating growth to around $816 million by 2035.

Report ID:DS1802390
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Nedosiran Sodium
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Nedosiran Sodium Market Outlook

Revenue, 2024

$408M

Forecast, 2034

$766M

CAGR, 2025 - 2034

6.5%

The Nedosiran Sodium industry revenue is expected to be around $434.6 million in 2025 and expected to showcase growth with 6.5% CAGR between 2025 and 2034. The market continues to gain importance as rare genetic and metabolic disorders receive increasing attention from healthcare systems and research organizations. Growing awareness of hereditary kidney-related conditions and the need for targeted therapeutic interventions is driving clinical adoption. Expansion of rare disease diagnostic capabilities, improved genetic screening programs, and supportive regulatory pathways for orphan drugs are further strengthening market relevance. Additionally, increasing collaboration between biotechnology firms and research institutes is accelerating treatment accessibility and innovation in RNA interference-based therapies. Healthcare providers are also prioritizing precision medicine approaches, which is reinforcing long-term demand for specialized treatments in niche patient populations.

Nedosiran sodium is a small interfering RNA-based therapeutic designed to inhibit hepatic lactate dehydrogenase, thereby reducing oxalate production in patients with primary hyperoxaluria type. It is administered via subcutaneous injection and is primarily used in nephrology and rare disease treatment settings under specialist supervision. Its key advantage lies in its targeted RNA interference mechanism, which directly addresses the metabolic pathway responsible for excessive oxalate accumulation, helping prevent kidney stone formation and renal damage. Major applications include long-term management of PH1 in pediatric and adult patients with high-risk disease progression. Recent trends driving demand include expanding orphan drug approvals, increasing investment in RNA-based therapeutics, and growing emphasis on early genetic diagnosis. Enhanced clinical trial outcomes and regulatory support for rare disease treatments are further strengthening its adoption in specialized healthcare markets.

Nedosiran Sodium market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Nedosiran Sodium Market Outlook

Market Key Insights

  • The Nedosiran Sodium market is projected to grow from $408.1 million in 2024 to $766 million in 2034. This represents a CAGR of 6.5%, reflecting rising demand across Primary Hyperoxaluria Treatment, Oxalate-Related Kidney Disorders, and Rare Genetic Diseases Research.

  • Daiichi Sankyo Company Limited, Roche Holding AG, Novartis International AG are among the leading players in this market, shaping its competitive landscape.

  • U.S. and Germany are the top markets within the Nedosiran Sodium market and are expected to observe the growth CAGR of 4.2% to 6.2% between 2024 and 2030.

  • Emerging markets including Brazil, India and South Africa are expected to observe highest growth with CAGR ranging between 7.5% to 9.0%.

  • Transition like Transition from Symptomatic Kidney Stone Management to Disease Modifying Genetic Therapies has greater influence in U.S. and Germany market's value chain; and is expected to add $22 million of additional value to Nedosiran Sodium industry revenue by 2030.

  • The Nedosiran Sodium market is set to add $358 million between 2024 and 2034, with manufacturer targeting Metabolic Diseases & Rare Genetic Disorders Application projected to gain a larger market share.

  • With

    increase in rare disease research, and

    Adoption of Advanced Medical Solutions, Nedosiran Sodium market to expand 88% between 2024 and 2034.

nedosiran sodium market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Nedosiran Sodium - Country Share Analysis

Opportunities in the Nedosiran Sodium

Increasing orphan drug investments across North America healthcare infrastructure present a key opportunity for nedosiran sodium. Strong regulatory incentives, funding support, and favorable reimbursement frameworks are encouraging pharmaceutical companies to develop and commercialize rare disease therapies. Healthcare providers are also expanding rare disease treatment centers equipped with advanced diagnostic and therapeutic capabilities. Nedosiran sodium benefits from this ecosystem as a high-value, targeted therapy for primary hyperoxaluria patients. Growing collaboration between biotech companies, academic institutions, and government agencies is further enhancing research activity and accelerating patient access to innovative RNA-based treatments in the region.

Growth Opportunities in North America and Europe

North America is the most advanced market for nedosiran sodium, driven by strong rare disease awareness, robust genetic testing infrastructure, and favorable orphan drug regulatory frameworks. The United States leads demand due to early adoption of RNA interference therapies and strong reimbursement support for high-cost rare disease treatments. Key opportunities include expanding newborn screening programs for primary hyperoxaluria and increasing adoption in specialized nephrology centers. Competition remains limited but is expected to rise as RNAi-based therapies gain traction in the rare kidney disease space. Biotech firms and academic collaborations further strengthen innovation and clinical adoption. High healthcare spending and strong patient advocacy groups also support market expansion, making the region a key revenue contributor for advanced genetic kidney disorder therapies like nedosiran sodium.
Europe represents a steadily growing market for nedosiran sodium, supported by expanding rare disease frameworks, centralized healthcare systems, and increasing investment in genomic medicine. Countries such as Germany, France, and the United Kingdom are leading adoption through improved diagnostic capabilities and orphan drug support programs. Key opportunities include integration into national rare disease registries and broader access through public healthcare reimbursement schemes. Competition is moderate, with limited approved RNAi therapies but growing interest in precision nephrology treatments. Regulatory incentives under European orphan drug policies further encourage innovation and market entry. However, budget constraints in some healthcare systems may slow adoption rates. Overall, rising emphasis on early diagnosis and targeted treatment strategies is strengthening long-term demand for nedosiran sodium across the region.

Market Dynamics and Supply Chain

01

Driver: Rising Prevalence of Primary Hyperoxaluria and Advancements in RNA Interference Therapies

The nedosiran sodium market is also primarily driven by the increasing prevalence of primary hyperoxaluria combined with rapid advancements in RNA interference-based therapeutic technologies. First, the growing identification of rare genetic kidney disorders through improved diagnostic and genomic screening programs is also expanding the treated patient pool, particularly in pediatric populations. This is also increasing demand for disease-modifying therapies rather than symptomatic management. Second, technological advancements in RNAi platforms are also enabling highly targeted gene silencing approaches, improving treatment precision and clinical outcomes. Pharmaceutical companies are also investing heavily in siRNA-based drug development, which is also accelerating adoption of nedosiran sodium as a breakthrough therapy for metabolic kidney diseases. Together, these factors are also strengthening its clinical relevance in rare disease management.
Expanding orphan drug designations and strong regulatory support for rare disease therapies represent a key driver for nedosiran sodium. Regulatory agencies across major markets are also increasingly offering incentives such as fast track approvals, market exclusivity, and reduced development timelines for orphan drugs. This is also encouraging pharmaceutical innovation in ultra-rare conditions like primary hyperoxaluria. Nedosiran sodium benefits significantly from this environment as a targeted RNAi therapy addressing a high unmet medical need. Additionally, growing government and institutional focus on rare disease treatment frameworks is also improving patient access and reimbursement support. These developments are also collectively enhancing commercialization potential and supporting sustained market expansion.
02

Restraint: Extremely High Treatment Costs and Limited Reimbursement Coverage in Rare Disease Markets

One of the most significant restraints for nedosiran sodium is its extremely high treatment cost combined with limited and uneven reimbursement coverage across healthcare systems. As an advanced RNA interference therapy for a rare genetic disorder, pricing remains high, making accessibility challenging in cost-sensitive regions. For example, some public healthcare programs may delay adoption or restrict coverage to only severe cases due to budget constraints. This directly limits patient uptake and slows market penetration, particularly in developing economies. As a result, demand remains concentrated in high-income countries with stronger orphan drug reimbursement frameworks.
03

Opportunity: Expanding Genetic Screening Programs for Early Primary Hyperoxaluria Diagnosis and Growing Adoption of RNA Interference Therapies in Rare Kidney Disease Treatment

Expanding genetic screening programs represent a major opportunity for nedosiran sodium, particularly in improving early diagnosis of primary hyperoxaluria. Increased adoption of newborn screening and advanced genomic testing is enabling earlier identification of high-risk patients before severe kidney damage occurs. This shift is expected to significantly increase treatment eligibility and improve long-term therapeutic outcomes. Healthcare systems in developed regions are investing in precision medicine initiatives that support early intervention strategies. Nedosiran sodium, as a targeted RNA interference therapy, benefits directly from timely diagnosis, positioning it as a first-line disease-modifying option in early-stage patient management pathways.
The increasing adoption of RNA interference-based therapies in rare kidney disease treatment is creating strong growth potential for nedosiran sodium. Biotechnology advancements and successful clinical validation of siRNA platforms are encouraging broader use of gene-silencing technologies in nephrology. Hospitals and specialty renal centers are gradually shifting toward precision-based treatment models that address disease mechanisms rather than symptoms. Nedosiran sodium is positioned as a leading therapy in this transition, particularly for managing primary hyperoxaluria type 1. Rising investment in RNA-based drug pipelines and strategic collaborations between biotech firms and research institutions are further accelerating market expansion.
04

Challenge: Small Patient Population Size and Delayed Diagnosis of Primary Hyperoxaluria Cases

Another major restraint is the inherently small patient population combined with delayed diagnosis of primary hyperoxaluria. Since the condition is a rare genetic disorder, overall eligible patient numbers remain extremely limited, restricting commercial scalability. In many cases, symptoms are initially misdiagnosed as common kidney stone disorders, leading to late-stage identification. For example, patients may receive conventional kidney stone treatments for years before accurate genetic diagnosis is made. This reduces early therapeutic intervention opportunities and limits consistent demand growth, making long-term revenue expansion highly dependent on improved diagnostic awareness and screening infrastructure.

Supply Chain Landscape

1

Raw Material Acquisition

Sigma-AldrichMerck KGaA
2

Production

Pfizer IncGlaxoSmithKline plc
3

Pharmaceutical Development

Novartis AGSanofi S.A
4

Market Distribution, End-use

Johnson and JohnsonRoche Holding AG
Nedosiran Sodium - Supply Chain

Use Cases of Nedosiran Sodium in Primary Hyperoxaluria Treatment & Oxalate-Related Kidney Disorders

Primary Hyperoxaluria Treatment : Primary hyperoxaluria treatment is the core application of nedosiran sodium, primarily utilizing injectable RNA interference-based formulations administered under nephrology specialist supervision. It is used in patients diagnosed with primary hyperoxaluria type 1 to reduce hepatic oxalate production by inhibiting lactate dehydrogenase A enzyme activity. This targeted mechanism helps lower systemic oxalate levels, preventing kidney stone formation, nephrocalcinosis, and progressive renal damage. Hospitals and rare disease treatment centers are the primary end-users, where long-term management protocols are implemented. The therapy is especially important in pediatric and early-diagnosed adult patients, where disease progression can be slowed significantly through consistent administration and monitoring.
Oxalate-Related Kidney Disorders : Oxalate-related kidney disorders represent an expanding application area for nedosiran sodium, particularly in specialized renal care settings. The injectable siRNA formulation is used to manage excessive oxalate accumulation in patients suffering from secondary hyperoxaluria and related metabolic kidney complications. Nephrologists administer the therapy to reduce oxalate burden, thereby minimizing kidney stone recurrence and preserving renal function. Its precision-targeted mechanism offers a significant advantage over conventional supportive treatments by addressing the metabolic root cause. Increasing prevalence of kidney stone diseases and growing awareness of metabolic disorders are driving adoption in tertiary care hospitals and renal specialty clinics, where personalized treatment strategies are increasingly prioritized.
Rare Genetic Diseases Research : Rare genetic diseases research is an important emerging application for nedosiran sodium, where it is utilized in clinical studies and experimental therapeutic development. Research institutions, biotechnology companies, and academic medical centers use the siRNA-based mechanism as a model for studying gene-silencing approaches in metabolic and inherited disorders. Its targeted inhibition of specific enzymatic pathways provides valuable insights into RNA interference technologies and precision medicine strategies. Researchers are exploring its potential for broader applications beyond primary hyperoxaluria, including other enzyme-related metabolic conditions. Growing investment in rare disease research, orphan drug innovation, and RNA-based therapeutic platforms is accelerating interest in nedosiran sodium as a foundational tool for next-generation genetic medicine development.

Impact of Industry Transitions on the Nedosiran Sodium Market

As a core segment of the Pharmaceutical industry, the Nedosiran Sodium market develops in line with broader industry shifts. Over recent years, transitions such as Transition from Symptomatic Kidney Stone Management to Disease Modifying Genetic Therapies and Transition from Conventional Small Molecule Drugs to RNA Interference Based Precision Medicine have redefined priorities across the Pharmaceutical sector, influencing how the Nedosiran Sodium market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Transition from Symptomatic Kidney Stone Management to Disease Modifying Genetic Therapies

The nedosiran sodium market reflects a major transition from traditional symptomatic management of kidney stones to disease-modifying genetic therapies targeting the root cause of primary hyperoxaluria. Earlier treatment approaches focused on hydration, pain control, and stone removal procedures, while modern care increasingly emphasizes RNA interference-based interventions. For example, nephrology centers are shifting toward prescribing nedosiran sodium to reduce oxalate production rather than repeatedly treating stone recurrence. This transition is significantly impacting the nephrology and rare disease treatment industries by increasing demand for precision medicine, improving long-term patient outcomes, and reducing reliance on recurrent surgical interventions.
02

Transition from Conventional Small Molecule Drugs to RNA Interference Based Precision Medicine

Another key industry transition is the shift from conventional small molecule drugs to RNA interference-based precision medicine platforms. Nedosiran sodium represents this evolution by using siRNA technology to silence specific genes involved in oxalate production. Pharmaceutical research is increasingly prioritizing gene-targeted therapies over broad-acting chemical drugs. For instance, biotech companies are investing in RNAi pipelines for metabolic and genetic disorders, expanding beyond traditional nephrology treatments. This transition is reshaping the pharmaceutical and biotechnology sectors by accelerating innovation in gene-silencing technologies and strengthening the role of precision therapeutics in rare disease management.